Dear Joe, You have resisted throwing out Excel
Post# of 36537
(Total Views: 298)
Posted On: 03/20/2020 4:24:17 PM
Dear Joe,
You have resisted throwing out Excellagen revenue projections when I and others have asked for them on conference calls.
Your reasoning for that was "That's the kind of thing OTC companies do." Yet you threw out that Excellagen had $450k in sales in November. And you tossed out that sales for 2 of the subsidiaries "increased by over 400%", which we now see from the 10-Q was insignificant.
Are we not at a point yet with Excellagen where we have some VAC approvals, a well-trained sales staff, and a pipeline of product where you can make a reasonable 12-month sales prediction?
I appreciate that the COVID vaccine work and the NGIO spin are the big dogs in the fight, but it would go miles and miles for us shareholders to have some actual revenue on the horizon from an existing product.
Thanks for any info you can pass along.
You have resisted throwing out Excellagen revenue projections when I and others have asked for them on conference calls.
Your reasoning for that was "That's the kind of thing OTC companies do." Yet you threw out that Excellagen had $450k in sales in November. And you tossed out that sales for 2 of the subsidiaries "increased by over 400%", which we now see from the 10-Q was insignificant.
Are we not at a point yet with Excellagen where we have some VAC approvals, a well-trained sales staff, and a pipeline of product where you can make a reasonable 12-month sales prediction?
I appreciate that the COVID vaccine work and the NGIO spin are the big dogs in the fight, but it would go miles and miles for us shareholders to have some actual revenue on the horizon from an existing product.
Thanks for any info you can pass along.
(2)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼